Drug Type Bispecific antibody |
Synonyms DIG-KT, PMC-001 |
Target |
Action antagonists |
Mechanism Tie-2 antagonists(TEK receptor tyrosine kinase antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | South Korea | 14 Jan 2019 | |
| Neoplasms | Preclinical | South Korea | 14 Jan 2019 |






